| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c7d999bb6ab478a7ed29b45a75d9190d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0c4322cb4de342be2dbedcbe0c278f6f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d6bf0a01c964aaaf50265d88a194deb8 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-122
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-531 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1138
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 |
| filingDate |
2017-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_14e4254561a6fb78bf10e237a5b33b46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2b6fb852042667cdea9cbfd59bd5e603
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c30aefc5cf856c26f155f107c9bb45d6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_34e9fe17c69d145a3b5614f19ae499aa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9af488b9a8263d862dcd5dc0efa210ce
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_90235255d12033ba920f245ab031c3b6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f86a453e788c4b237bae64468e391aa2 |
| publicationDate |
2019-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3452594-A1 |
| titleOfInvention |
Rnai therapy for treatment and/or prevention of glaucoma |
| abstract |
The present invention is directed to an RNAi-inducing agent capable of reducing and/or inhibiting the expression of proteins associated with the tight junction complex joining Schlemm's canal endothelial cells (SCEC) in the eye of a subject for use in the prevention and/or treatment of glaucoma. Specifically, the RNAi-inducing agent is capable of reducing and/or inhibiting the expression of proteins expressed in the tight junction complex or supporting the tight junction complex joining Schlemm's canal endothelial cells (SCEC) in the eye of a subject for use in the prevention and/or treatment of glaucoma. Methods using this RNAi-inducing agent are also contemplated. |
| priorityDate |
2016-05-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |